Heart failure & cardiomyopathies
Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial
Authors' conclusion
In patients with heart failure with reduced ejection fraction enrolled in EMPEROR-Reduced, those with an ICD (vs non-ICD) experienced a lower risk of SCD regardless of empagliflozin treatment.
Study context
- Population
- Patients with HFrEF enrolled in EMPEROR-Reduced, on placebo or empagliflozinmatched cohort
- Participants
- 1,674 patients
- Comparison
- Implantable cardioverter-defibrillator (ICD) vs no ICD
- ICDn = 837
- Non-ICDn = 837reference
- Primary endpoint
- Sudden cardiac death (SCD)
Methodological detailspropensity-score matched
- Propensity-score matched
Primary result
As reported in the abstract
ICD vs Non-ICDHazard ratio (95% CI)
Empagliflozin arm
0.59(0.26–1.3)
Placebo arm
0.31(0.13–0.74)
Original publication
Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial. JACC Heart Fail. Published 2 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →